In this 96-week , phase 2b study , 97 patients were randomized and treated with lersivirine 750 mg qd ( n = 31 ) , lersivirine 1,000 mg qd ( n = 32 ) , and etravirine 200 mg bid ( n = 34 ) , plus one optimized nucleoside reverse transcriptase inhibitor and darunavir/ritonavir 600/100 mg bid .